Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Eagle Capital Management Ravenel B. Curry III | “UnitedHealth Group has significant scale advantages in a consolidated industry that outgrows the overall economy. The industry moves with its own cycle and, over the last several years, has faced cost/price pressures in Medicare Advantage and Medicaid. Even the largest firms are earning poor margins. We believe conditions have bottomed out and that we are transitioning to a multi-year improvement in margins and earnings. Since returning as CEO at UnitedHealth last year, Stephen Hemsley and the management team have been correcting some of the company's missteps. Recent results provide growing evidence that the turnaround is well on track.” | NEUTRAL | Q2 2026 Aug 4, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “A year ago, we wrote to you about the travails of our UnitedHealth investment. The stock lost over half its value in about a month, an extraordinary change for a steady business that serves as the health insurance provider to one in seven Americans. There were two core problems the company faced: unexpectedly higher healthcare usage and chasing unprofitable business. The company has since executed on its turnaround plan, raising rates to reflect the higher usage and getting out of markets it couldn't make money in. We bought more after the stock tanked, and it has since rebounded, returning 37% over the past year and 80% off its lows. We think there's more to come. The stock added 2.5% to performance in the quarter.” | NEUTRAL | Q2 2026 Aug 3, 2026 | View Pitch |
Vulcan Value Partners - Focus Vulcan Value Partners, LLC | “UnitedHealth is the largest private health insurer in the country. We purchased UnitedHealth Group a little over a year ago after its stock price had declined from approximately $600 per share to under $300 per share as the company missed earnings and replaced its CEO. As a reminder, UnitedHealth Group has been on the MVP list for a number of years and we have owned it successfully several times over the last decade. After a thorough review of the company's competitive position and assessment of the new management team, we determined that UnitedHealth Group's value was stable and that the company should be able to return to steady earnings growth within a year or so. Since that time the company has executed even better than we expected. 'Mr. Market' is beginning to recognize what we saw a year ago and UnitedHealth Group's discounted shares are beginning to recover. In fact, the company's stock increased by more than 35% through the first half of the quarter prior to our exit while our value remained stable. Following our discipline, we sold UnitedHealth Group in our Focus portfolio to reallocate capital into meaningfully more discounted companies whose values are compounding at attractive double-digit rates.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Vulcan Value Partners - All Cap C.T. Fitzpatrick | “UnitedHealth is the largest private health insurer in the country. We purchased UnitedHealth Group a little over a year ago after its stock price had declined from approximately $600 per share to under $300 per share as the company missed earnings and replaced its CEO. As a reminder, UnitedHealth Group has been on the MVP list for a number of years and we have owned it successfully several times over the last decade. After a thorough review of the company's competitive position and assessment of the new management team, we determined that UnitedHealth Group's value was stable and that the company should be able to return to steady earnings growth within a year or so. Since that time the company has executed even better than we expected. 'Mr. Market' is beginning to recognize what we saw a year ago and UnitedHealth Group's discounted shares are beginning to recover. Following our discipline, we sold UnitedHealth Group in our All Cap portfolio to reallocate capital into meaningfully more discounted companies whose values are compounding at attractive double-digit rates.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Vulcan Value Partners Focus Plus Vulcan Value Partners LLC | “UnitedHealth is the largest private health insurer in the country. We purchased UnitedHealth Group a little over a year ago after its stock price had declined from approximately $600 per share to under $300 per share as the company missed earnings and replaced its CEO. As a reminder, UnitedHealth Group has been on the MVP list for a number of years and we have owned it successfully several times over the last decade. After a thorough review of the company's competitive position and assessment of the new management team, we determined that UnitedHealth Group's value was stable and that the company should be able to return to steady earnings growth within a year or so. Since that time the company has executed even better than we expected. 'Mr. Market' is beginning to recognize what we saw a year ago and UnitedHealth Group's discounted shares are beginning to recover. In fact, the company's stock increased by more than 35% through the first half of the quarter prior to our exit while our value remained stable. Following our discipline, we sold UnitedHealth Group in our Focus portfolio to reallocate capital into meaningfully more discounted companies whose values are compounding at attractive double-digit rates.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Vulcan Value Partners - Large Cap C.T. Fitzpatrick | “UnitedHealth is the largest private health insurer in the country. We purchased UnitedHealth Group a little over a year ago after its stock price had declined from approximately $600 per share to under $300 per share as the company missed earnings and replaced its CEO. As a reminder, UnitedHealth Group has been on the MVP list for a number of years and we have owned it successfully several times over the last decade. After a thorough review of the company's competitive position and assessment of the new management team, we determined that UnitedHealth Group's value was stable and that the company should be able to return to steady earnings growth within a year or so. Since that time the company has executed even better than we expected. 'Mr. Market' is beginning to recognize what we saw a year ago and UnitedHealth Group's discounted shares are beginning to recover.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “We re-established positions in two previously owned managed care companies, UnitedHealth Group Incorporated and Elevance Health, Inc. Both companies manage diversified portfolios, providing insurance and health care services to Commercial, Exchange, Medicaid and Medicare Advantage members. We believe that the insurance cycle is turning more favorable for these companies, particularly in their Medicare Advantage businesses. After several years of elevated utilization trends, inadequate reimbursement, and regulatory challenges coupled with aggressive pricing to drive share gains, which drove operating margins to depressed levels, UnitedHealth and Elevance have exited unprofitable Medicare Advantage markets and products, right-sized benefits, and are now in the process of rebuilding profitability. We further think that the application of AI will enable them to take a significant bite out of administrative costs as well. Finally, we believe that the earnings power of both companies is well above current levels assuming they can approach their long-term target margins over the next few years. If we further assume a reasonable multiple on future earnings power, we believe there is substantial upside in both stocks.” | NEUTRAL | Q2 2026 Jul 23, 2026 | View Pitch |
Janus Henderson Forty Fund Nick Schommer, Brian Recht | “Stock selection was a strong driver of relative performance, with UnitedHealth Group a top relative contributor. Last year, the health insurer faced business headwinds that pressured its stock performance. We were reassured when the company announced a management change and brought back former CEO Stephen Hemsley. Hemsley announced an improvement plan aimed at cost management, operational improvements, and margin expansion. These efforts appear to be proceeding ahead of schedule, helping the company to exceed its first-quarter earnings targets. Additionally, UnitedHealth has announced significant AI investments, which the company hopes will help drive further customer engagement and productivity gains.” | BULL | Q2 2026 Jul 17, 2026 | View Pitch |
Latitude Global Fund Freddie Lait | “At the beginning of the quarter, we significantly added to UnitedHealth, approximately doubling the size of the position. A 2.5% deviation of the $400bn healthcare costs paid by UnitedHealth annually ” | BULL | Q2 2026 Jul 13, 2026 | View Pitch |
VVP Q2 Letter 06.30.26 Portfolio Manager | “UnitedHealth was purchased following a severe sell-off and leadership change, with the manager correctly identifying that its underlying competitive advantages remained intact. The company has since exceeded operational expectations, and its stock is beginning to recover as the market recognizes its earnings stability.” | BULL | Q2 2026 Jun 30, 2026 | View Pitch |
Auxier Asset Management Jeff Auxier | “UnitedHealth has been a major laggard for the past quarter and year. However, since CEO Stephen Hemsley's return last May operating performance has been improving. We made over a fivefold return under” | BULL | Q1 2026 May 11, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “UnitedHealth Group was a meaningful contributor during the quarter. Shares recovered from prior weakness as investors gained confidence in the company's ability to navigate medical cost trends and regulatory scrutiny. We continue to believe that UnitedHealth's vertically integrated model, combining insurance operations with Optum's care delivery and pharmacy benefit management capabilities, provides a structural cost advantage over peers. The company generates substantial free cash flow and has a long history of disciplined capital allocation through dividends and share repurchases. While near-term utilization trends can create earnings volatility, we believe the long-term demand for managed care and data-driven health services remains intact. Our position reflects confidence in management's ability to compound earnings at an attractive rate over time. BSD Analysis: UnitedHealth Group remains a cornerstone of the managed care sector, leveraging its dual-engine model of insurance services and the Optum health services platform. Following a transitional year of higher medical utilization and regulatory shifts, the company is entering 2026 with a focus on margin restoration through disciplined premium repricing. Analyst consensus points to a significant recovery as the firm navigates Medicare Advantage headwinds and stabilizes its medical loss ratio. The massive scale of Optum provides a defensive moat, as its data-driven clinical services continue to capture a larger share of the value-based care market. With a consistent track record of double-digit dividend growth and aggressive share repurchases, UNH offers a compelling mix of defensive stability and long-term capital appreciation.” | BULL | Q4 2025 Feb 12, 2026 | View Pitch |
Sequoia Fund Arman Gökgöl-Kline, John Harris, Trevor Magyar | “Our investments in UnitedHealth Group Inc. (“United”) are instructive in this regard. We initiated the position opportunistically, capitalizing on a 2019 share price swoon precipitated by “Medicare for All” fears during the runup to the 2020 presidential election. United's business performed well out of the gates, bolstered by Covid-induced swelling of government-funded healthcare rolls combined with subdued utilization. We recognized that the pleasing results during Covid had not changed our assessment of fundamental value and that valuations were on the high side of fair. Accordingly, we sold almost half of our shareholdings over the course of 2022. As it turned out, the managed care industry then entered a multi-year period of significant fundamental pain driven by rising and volatile utilization. United's shares declined by over 33% in 2025, making it the worst performing position in the portfolio. We continue to believe United plays an essential role in the healthcare system and may prove attractive over the long term despite elevated policy risk. BSD Analysis: UnitedHealth Group offers a robust 2026 outlook with a forecast for earnings per share of at least $17.75, driven by improved margins and strong contributions from Optum Rx. While total revenue may face slight headwinds compared to 2025, the company's health benefits business continues to cater to nearly 50 million people. Elevated medical costs and lower-than-expected Medicare Advantage rate increases from regulators remain the primary watchpoints for the current cycle. However, the firm's massive cash position of over $28 billion provides the liquidity needed to navigate shifting risk-based membership trends. Management is focusing on operational productivity and Optum's diverse service lines to offset rising medical care ratios. UnitedHealth remains a quintessential defensive giant, leveraging its unparalleled scale to manage the complexities of US healthcare.” | BULL | Q4 2025 Jan 30, 2026 | View Pitch |
Cullen Enhanced Equity Income Fund Portfolio Manager | “Shares of UnitedHealth Group (UNH) were purchased in the strategy during the quarter. UnitedHealth is the largest diversified managed care organization in the US, with leading positions across commercial insurance, Medicare Advantage, Medicaid, and a differentiated healthcare services platform through Optum. After a period of elevated medical cost trends, management has taken proactive steps to reset margins and improve earnings quality, including disciplined repricing, targeted cost actions, and selective portfolio rationalization. Within Medicare Advantage, the company expects to reduce membership by approximately 1 million lives in 2026 to prioritize profitability and restore margin discipline. At Optum Health, management is restructuring the business, including a roughly 10% reduction in value-based care exposure, to improve sustainability and align with long-term margin objectives. As these actions take effect and investments normalize, UnitedHealth's scale, diversified revenue streams, and integrated Optum platform position the company for improving profitability and more consistent earnings growth over time. UNH trades at 19.9x 2026 EPS with a 2.6% dividend yield. BSD Analysis: UnitedHealth is healthcare scale weaponized. Insurance, pharmacy benefits, and Optum services create vertical integration few rivals can match. Political scrutiny is constant, but demand for managed care isn't disappearing. Margins reflect execution discipline rather than generosity. Cash flow is massive and predictable. Regulatory risk is the permanent overhang. This is not a speculative healthcare name. It's managed care infrastructure with embedded leverage.” | BULL | Q4 2025 Jan 13, 2026 | View Pitch |
Davis Opportunity Fund Chris Davis | “Within healthcare, we were very opportunistic throughout 2025 and the prior year, investing in a decisive way when shares of leading managed care insurers stumbled as operating costs surged rather unexpectedly for the group. Our key thesis was that these businesses were trading at low to very reasonable multiples on depressed earnings relative to historical levels, yet stood a good chance of recovering, possibly in dramatic fashion. Seemingly small margin improvements on low profit margins can translate into very large percentage increases in structural earnings power. We believe the market's valuations for these portfolio companies underestimated the potential for a rebound in their bottom-line economics. UnitedHealth is a representative investment in this category. BSD Analysis: UnitedHealth's moat is scale plus vertical integration across insurance, care delivery, and data through Optum. Complexity is a feature, not a bug—it deters competitors and locks in customers. Pricing power exists structurally, though politically constrained. Optum is the real growth engine, turning healthcare inefficiency into recurring revenue. Regulatory scrutiny is constant but rarely disruptive in practice. Execution missteps show up fast due to sheer size. The bull case is continued shift toward value-based care and data-driven services. The bear case is policy shock targeting integrated models. UnitedHealth compounds because it sits at the center of U.S. healthcare plumbing.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
ClearBridge Investments Large Cap Growth Strategy Erica Furfaro, Margaret Vitrano | “The performance of our health care holdings was another disappointment. UnitedHealth Group, a consistent contributor in the portfolio's stable bucket for more than a decade, suffered from a combination of negative sentiment and severe mismanagement that caused the stock to lose about half its value in 2025 by the time we exited the position in August. While we had been trimming UnitedHealth consistently since the fourth quarter of 2024, we also believed the company deserved some leeway to turn things around given its long-term track record. In hindsight, UnitedHealth disclosure had always been below average due to the nature of its regulated businesses, as well as the size and scope of the company's operations, but that lack of disclosure also made it hard to assess the execution issues that the company faced in 2025. Ultimately, despite a decade of solid returns, we lost confidence in UnitedHealth's ability to navigate a turnaround under new leadership and exited the position. BSD Analysis: UnitedHealth's moat is vertical integration executed at national scale. Optum turns claims data into underwriting intelligence, provider leverage, and cost control that smaller insurers cannot replicate. Switching costs are embedded not in contracts, but in workflows, data, and employer dependence. Regulatory scrutiny is the ever-present risk, but size also makes UNH politically hard to destabilize outright. Medical cost ratios fluctuate, yet pricing power resets annually. Growth is steady rather than flashy, which masks just how dominant the platform is. The real threat is policy shock, not competition. Valuation reflects durability more than upside optionality. UnitedHealth is healthcare infrastructure pretending to be an insurer.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “UnitedHealth rebounded after earlier losses, adding 0.9% to the fund. Investors were encouraged by the new CEO's optimistic comments and Berkshire Hathaway's initiation of a position. The fund added t” | BULL | Q3 2025 Oct 24, 2025 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “UnitedHealth rebounded after earlier losses, adding 0.9% to the fund. Investors were encouraged by the new CEO's optimistic comments and Berkshire Hathaway's initiation of a position. The fund added to its holdings during the quarter. BSD Analysis: UnitedHealth's rebound reflects renewed investor confidence following leadership change and strategic execution. With strong Optum growth, stable medical ratios, and recurring cash flow, the firm trades below intrinsic value despite near-term cost noise.” | BULL | Q3 2025 Oct 24, 2025 | View Pitch |
The Bristol Gate U.S. Equity Strategy Achilleas Taxildaris | “UnitedHealth was added via reallocation from outperforming positions. The firm's scale, diversified earnings mix, and data-driven efficiency make it a long-term compounder in managed care. BSD Analysis: Bristol Gate views UNH as the premier U.S. healthcare franchise with durable competitive advantages across insurance and analytics. Optum's consistent growth, cost synergies, and expansion into value-based care sustain high single-digit earnings growth. Strong balance sheet, dividend growth, and valuation near historical lows offer an appealing entry point.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
The London Company Income Equity Brian Campbell | “UnitedHealth Group (UNH) – UNH is the largest and most diversified health insurer in the U.S., anchored by two complementary platforms: UnitedHealthcare and Optum. This integrated model gives UNH unmatched scale and insight into healthcare costs, enabling both efficiency and improved outcomes. Its vast provider networks, local dominance, and data-driven capabilities form durable competitive advantages and high barriers to entry. Long-term growth is supported by powerful demographics, as the aging U.S. population drives steady Medicare Advantage enrollment—a core UNH strength. While near-term elevated medical costs have pressured margins and weighed on the stock, we view these headwinds as temporary. UNH is already repricing future plans to reflect higher costs, supporting a gradual return to historical margin levels. With a recurring revenue base, diversified earnings, and financial strength, UNH offers attractive downside protection. At today's valuation, we see a compelling opportunity to own a structural growth leader with resilient cash flows. BSD Analysis: UNH's integrated model and Optum's analytics moat provide sustainable growth. Temporary medical cost inflation is being repriced into 2026 contracts, restoring margin visibility. With 13% EPS CAGR, consistent buybacks, and a 1.5% yield, UNH remains the premier managed care compounder at an undemanding multiple.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Mott Capital Management Michael Kramer | “We redeployed some of our defensive positioning by acquiring UnitedHealth on May 2. UnitedHealth is the largest health insurance company in the United States and recently faced pressure due to disappointing first-quarter results and the resignation of its CEO. Having tracked this company closely for years, I viewed the investment as a high-risk, high-reward opportunity. Although there's always a chance the stock could decline further, the expectation is that UnitedHealth will resolve its current challenges, creating significant upside. This situation is reminiscent of our previous experience with Boeing, where a turnaround took years but eventually paid off. Considering the risk-reward balance, the decision felt justified, betting on the idea that UnitedHealth is too significant to fail entirely, and even if dismantled, substantial value would remain. :contentReference[oaicite:1]{index=1} BSD Analysis: UnitedHealth continues to dominate U.S. healthcare with a dual-engine model: insurance scale plus Optum's services, care delivery, and analytics platform. Optum is steadily shifting the mix toward higher-margin, less cyclical revenue. United's data advantage allows it to manage risk better than peers, making underwriting more consistent across cycles. Demographics and chronic-care prevalence support long-term growth in insured lives. Regulatory overhang never disappears, but the business has navigated decades of policy shifts with barely a dent. Cash flow is massive and reliable. UNH remains the cornerstone compounder of the sector.” | BULL | Q2 2025 Aug 4, 2025 | View Pitch |
Alger Spectra Fund Patrick Kelly, Dan Chung, Ankur Crawford | “UnitedHealth Group integrates insurance benefits, primary care, pharmacy services, and data analytics, leveraging its scale to effectively address rising healthcare costs. Historically, the company has delivered strong double-digit earnings growth, driven by steady revenue expansion as more employers and payers adopt its solutions. However, this growth trajectory has recently been disrupted due to higher-than-anticipated utilization rates among Medicare Advantage (MA) members. Shares detracted from performance during the quarter after fiscal first-quarter earnings came in lower than expected, and management reduced full-year guidance, citing unexpected cost pressures from increased medical visits and specialist care early in the year. This was partly caused by higher-than-expected healthcare utilization from new MA members who had switched from competitors. In our view, profitability could improve next year as UnitedHealth and the broader MA industry implement higher pricing and government reimbursement rates adjust to reflect current utilization patterns. BSD Analysis: UnitedHealth is still the 800-pound gorilla of managed care — the only player with real scale advantages across data, claims processing, provider integration, and risk scoring. The Change Healthcare cyber mess was a black eye, but it didn't dent the underlying economics: UNH controls the plumbing of U.S. healthcare, and everyone eLondon Stock Exchange pays rent. Optum remains a growth monster with margins most health providers would kill for, and its data flywheel keeps getting stronger as more care moves into value-based models. Medicare Advantage noise is temporary; UnitedHealth's pricing power and actuarial precision aren't. Cash flow remains enormous, the balance sheet is bulletproof, and UNH historically comes out of regulatory stress stronger, not weaker. This is still the healthcare stock everyone eLondon Stock Exchange quietly benchmarks against.” | BULL | Q2 2025 Jul 15, 2025 | View Pitch |
Patient Capital Management Christina Siegel Malbon | “UnitedHealth Group (UNH $302.91) represents exactly the kind of opportunity we like. It fell from a high of $630 late last year to a low of $249 in the second quarter giving us the chance to enter. A long-time darling known for consistently beating earnings, investors reacted poorly to a barrage of bad news (earnings disappointment, guidance pull, CEO change, DoJ investigation). There are several challenges pressuring United's earnings. We believe it's a classic underwriting cycle that can be remedied over time. United is a great company with high returns on capital. The new CEO Steve Hemsley did an excellent job running the company during his previous tenure. We see earnings power of $40-45 per share in 3-5 years. The company historically traded at 16-17x earnings. Using the low ends of these ranges implies UNH will trade back to $640, upside of 111%. If that takes 5 years, it will compound at 16% per year, which should nicely outperform the market. BSD Analysis: UnitedHealth Group is a high-quality healthcare titan whose unique, integrated model provides an unbreakable moat and delivers predictable, above-market growth. The core thesis is centered on the Optum segment—the company's tech, pharmacy, and care delivery arm—which is the true compounding engine. Optum's ability to use proprietary data and technology to optimize costs and improve outcomes is the structural driver of margin expansion and superior efficiency. The company's growth is secured by predictable premium revenues and Optum's increasing contribution, maintaining a focus on Value-Based Care. Optum Health now serves more than 4 million patients in this fully accountable model. The stock offers a defensive, double-digit growth profile, combining the stability of a payer with the high-growth optionality of a tech-enabled health services provider.” | BULL | Q2 2025 Jul 11, 2025 | View Pitch |
Polaris Global Equity Bernard Horn | “Health care holdings detracted most from portfolio performance. UnitedHealth Group's stock dropped to multi-year lows due to a sharp spike in medical costs and the company's withdrawal of its full-year guidance. The surprise resignation of CEO Andrew Witty and his replacement by former CEO Stephen Hemsley further rattled the market. Ongoing regulatory scrutiny, including a Department of Justice investigation into Medicare Advantage billing practices, added to the negative sentiment surrounding the stock. BSD Analysis: UnitedHealth's dual-engine model — insurance scale plus Optum's healthcare services — makes it the most powerful profit generator in U.S. healthcare. Optum's move into physician groups and advanced analytics creates operating leverage others can't match. Managed care is politically sensitive, but UNH has survived every regulatory storm intact. Cash generation is astonishingly consistent. The business gets better with scale, not worse. It's the anchor stock for healthcare exposure. Hard to beat, harder to replace.” | BEAR | Q2 2025 Jun 30, 2025 | View Pitch |
Hardman Johnston Global Equity Cassandra A. Hardman | “We initiated a position in UnitedHealth Group early in the second quarter... However, United Health reported Q1 earnings with a significant increase in medical loss ratio, and they sharply lowered 2025 guidance. Given the extent of the uncertainty in forward guidance and risk of continued mis-execution in insurance pricing, we decided to exit the position. Subsequently, there was a change in CEO, removal of 2025 guidance, and a potential Department of Justice criminal investigation into United Health's Medicare Advantage business. BSD Analysis: UnitedHealth Group is a high-quality healthcare titan whose unique, integrated model provides an unbreakable moat and delivers predictable, above-market growth. The core thesis is centered on the Optum segment—the company's tech, pharmacy, and care delivery arm—which is the true compounding engine, consistently growing revenue faster than the core insurance business (UnitedHealthcare). Optum's ability to use proprietary data and technology to optimize costs and improve outcomes for both its own members and external clients is the structural driver of margin expansion and superior efficiency. The company's long-term guidance of 13% to 16% adjusted EPS growth is virtually unmatched in the large-cap sector, secured by predictable premium revenues and Optum's increasing contribution. The stock offers a defensive, double-digit growth profile that is essential for a balanced portfolio, combining the stability of a payer with the high-growth optionality of a tech-enabled health services provider.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Madison Sustainable Equity Fund Maya Bittar, Dave Geisler | “UnitedHealth Group withdrew full-year guidance, announced a CEO change, and reported earnings below expectations due primarily to Medicare Advantage funding cuts and higher-than-expected medical costs. The former CEO returned, purchasing $25 million in shares, signaling confidence. Analysts expect Medicare Advantage profitability to recover over the next year as funding improves and cost trends stabilize. BSD Analysis: UnitedHealth Group is a high-quality healthcare titan whose unique, integrated model provides an unbreakable moat and delivers predictable, above-market growth. The core thesis is centered on the Optum segment—the company's tech, pharmacy, and care delivery arm—which is the true compounding engine. Optum's ability to use proprietary data and technology to optimize costs and improve outcomes is the structural driver of margin expansion and superior efficiency. The stock offers a defensive, double-digit growth profile, combining the stability of a payer with the high-growth optionality of a tech-enabled health services provider.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
L1 Capital International Fund David Steinthal | “UnitedHealth announced a material downgrade to 2025 profit expectations in conjunction with its first quarter results and followed up a few weeks later with a further profit downgrade and the "resignation" of then CEO, Andrew Witty. We are extremely disappointed with the performance and management of UnitedHealth, and our own assessment of the business. ... UnitedHealth has been impacted by sector issues including reduced reimbursement rates from Government sources as well as increased medical expenses. In our view UnitedHealth is also dealing with a number of company-specific operational issues. ... However, recent events have caused us to lose confidence in our assessment of the business and management. Some of the key senior management team have either resigned, been fired or murdered (the CEO of the insurance division, Brian Thompson, was tragically killed in late 2024...). We are unsatisfied with some of the explanations given by management for the series of profit downgrades and consider there may be more bad news to come. Having confidence in management is a threshold issue for our assessment of Quality and making or holding an investment in a company. ... The Fund no longer holds an investment in UnitedHealth and currently we do not consider the company to be investable for us. BSD Analysis: UnitedHealth Group is a high-quality healthcare titan whose unique, integrated model provides an unbreakable moat and delivers predictable, above-market growth. The core thesis is centered on the Optum segment—the company's tech, pharmacy, and care delivery arm—which is the true compounding engine. Optum's ability to use proprietary data and technology to optimize costs and improve outcomes is the structural driver of margin expansion and superior efficiency. The stock offers a defensive, double-digit growth profile, combining the stability of a payer with the high-growth optionality of a tech-enabled health services provider.” | BEAR | Q2 2025 Jun 30, 2025 | View Pitch |
“UnitedHealth Group (UNH) is the largest integrated healthcare services company in the United States. We established a starter position in UNH after the company's Q1 2025 earnings implosion and continued to build our position as the stock price weakened. While we don't think UNH is the defensive compounder that many investors thought it to be, we do think that the stock offers quite an asymmetric risk/reward following a ~50% drawdown from the recent highs in April. The company faces elevated Medicare Advantage utilisation, challenges in value-based care risk adjustment, and the V28 transition. These issues led to withdrawn guidance and a sharp share price decline. At 12-15x a normalized 2026 EPS range of $24.0-$25.0, UNH would trade between $290-$375, offering limited downside from current prices and enough upside for an attractive trade. BSD Analysis: UnitedHealth Group is a high-quality healthcare titan whose unique, integrated model provides an unbreakable moat and delivers predictable, above-market growth. The core thesis is centered on the Optum segment—the company's tech, pharmacy, and care delivery arm—which is the true compounding engine. Optum's ability to use proprietary data and technology to optimize costs and improve outcomes is the structural driver of margin expansion and superior efficiency. The company's growth is secured by predictable premium revenues and Optum's increasing contribution, maintaining a focus on Value-Based Care. The stock offers a defensive, double-digit growth profile, combining the stability of a payer with the high-growth optionality of a tech-enabled health services provider.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch | |
Bretton Fund Stephen Dodson and Raphael de Balmann | “UnitedHealth faced heightened headlines and legal controversy following the assassination of its insurance CEO, alongside ongoing political scrutiny over claims management. Management remains committed to the thesis, noting the US healthcare system's structural reliance on private entities to negotiate pricing and manage care.” | BULL | Q4 2024 Dec 31, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
